Improving Patient Adherence and Quality
of Life in Managing B-Cell Malignancies with BTK Inhibitors:
Strategies for Anticipating, Recognizing, and Managing Adverse
Events
A continuing medical education activity sponsored by NAMCP and AAMCN.
Expert Perspectives on the Role of
BTK Inhibitors in Chronic Lymphocytic Leukemia (CLL): What Managed
Care Needs to Know for Improved Clinical and Economic Outcomes is a
3-part live webinar series that
will provide attendees with the latest information in the management
of CLL
This is Part 2 of the series focusing on anticipating, recognizing,
and managing adverse events
This activity is an archive from the webinar held April 3, 2020
This activity is valid from May 1, 2020 to
May 1, 2022 |
Instructions for CME/CNE: Complete the pre-test, listen to the audio
and view the slides, complete the post test, complete the evaluation
form and hit submit. You will be asked to enter your name and email
address on the pre-test, evaluation and post-test. If you close your
internet browser without completing the post test, you will have ONE
more opportunity to complete. A score of 70% must be achieved on the
post test to receive continuing education credits. If you do not
pass the post test after two attempts, you will not be eligible to
try again. Once you complete the evaluation form and score 70% or
higher on your post test, you will automatically be given your
certificate.
To print or save your certificate, you will need to click on the
“download” button and either print or save.
|
Audience: This activity is intended for
healthcare professionals practicing in managed care environments.
This presentation is supported by
educational grants from
AstraZeneca and Pharmacyclics LLC, an AbbVie Company and Janssen
Biotech, Inc.
Description:
Bruton's tyrosine kinase (BTK) is an enzyme that in humans is
encoded by the BTK gene. BTK is abundantly expressed and
constitutively active in the pathogenesis of B cell hematological
malignancies. Therefore, BTK is considered as an attractive target
for treatment of B-cell malignancies. These options, known as BTK
inhibitors, have changed the treatment paradigm in several different
B-cell malignancies in recent years. These agents differ in dosing,
efficacy, and toxicities, and as these options for B-cell
malignancies grow, it is essential to understand their clinical and
economic role in the treatment paradigm to offer patients the safest
and most efficacious treatment, while also controlling costs.
Upon completion of this
activity, participants will be able to:
-
Compare BTK inhibitors in B-Cell
malignancies, with a focus on CLL, including mechanisms of
action, delivery methods, dosing and scheduling, efficacy,
safety, interactions, and ease of use
-
Discuss strategies to mitigate and
manage predictable toxicities that have been reported with the
use of BTK inhibitors in B-Cell malignancies, with a focus on
CLL
-
Discuss methods to communicate
effectively with cancer patients and the multidisciplinary team
to understand and address the needs of each patient around BTK
inhibitors and improve treatment adherence, quality of life, and
survival outcomes
-
Review how treatment strategies can
be affected by adverse events based on patient’s individualized
needs
Faculty: |
Matthew Davids, MD, MMSc
Assistant Professor of Medicine
Harvard Medical School
Associate. Director, CLL Center
Dana-Farber Cancer Institute |
Disclosure:
|
Dr. Davids
serves on an advisory board for AbbVie, Ascentage Pharma,
Astra-Zeneca, Celgene, Genentech, Janssen, Pharmacyclics,
and TG Therapeutics. He serves as a consultant for
AbbVie, Adaptive Biotechnologies, Astra-Zeneca, BeiGene,
Genentech, Janssen, MEI Pharma, Pharmacyclics, Research
to Practice, and Verastem. He has received grants or
research from Ascentage Pharma, Astra-Zeneca, Genentech,
MEI Pharma, Pharmacyclics, Surface Oncology, TG
Therapeutics, and Verastem. His presentation has been
peer reviewed for any bias. |
|
Planning Committee:
Bill Williams,
MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships
to disclose.
Will Williams has no relevant financial relationships to
disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial
relationships to disclose.
NAMCP and/or the presenter
has copyright or has received permissions for use of
materials provided in this activity. |
Accreditation & Designation
This activity has been planned and implemented in accordance with
the accreditation requirements and policies of the Accreditation
Council for Continuing Medical Education (ACCME) through the joint
providership of the National Association of Managed Care Physicians
(NAMCP) and American Association of Managed Care Nurses (AAMCN). The
National Association of Managed Care Physicians is accredited by the
ACCME to provide continuing medical education for physicians.
NAMCP designates this enduring material for a maximum of 1 AMA
PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their
participation in the activity.
The American Association of Managed Care Nurses is accredited as a
provider of nursing continuing professional development by the
American Nurses Credentialing Center's Commission on Accreditation.
Nurses who complete this activity and achieve a passing score will
receive 1 hour in continuing
nursing credit.
This activity has been approved by the American Board of Managed
Care Nursing for 1.0 contact hours toward CMCN recertification
requirements.
This presentation is supported by
educational grants from
AstraZeneca and Pharmacyclics LLC, an AbbVie Company and Janssen
Biotech, Inc.
NAMCP and/or this website does not
provide medical advice, diagnosis or treatment. NAMCP does not
endorse or imply endorsement of the content on any linked website.
This website is to be used as an informational resource. With any
health related concern, consult with your physician or healthcare
professional.
Click Here To Continue |